Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from CSL ( (AU:CSL) ).
CSL Limited announced the cessation of 50,194 securities due to the lapse of conditional rights, as the conditions were not met or became unachievable. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting the challenges in meeting certain operational conditions.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and provision of innovative medicines and therapies. The company is known for its work in the areas of vaccines, blood plasma derivatives, and other biopharmaceutical products, serving a global market.
Average Trading Volume: 1,361,230
Technical Sentiment Signal: Sell
Current Market Cap: A$86.86B
See more insights into CSL stock on TipRanks’ Stock Analysis page.